SCHEMBL3822363

SCHEMBL3822363

CCNc1nc2cc(C)ccc2o1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.59
NPC1 O15118 6/20 0.59
MAPT P10636 5/20 0.59
ALDH1A1 P00352 6/20 0.50
SMN1; SMN2 Q16637 5/20 0.50
KDM4E B2RXH2 5/20 0.50
HPGD P15428 5/20 0.50
HSD17B10 Q99714 5/20 0.50
TP53 P04637 4/20 0.50
CASP3 P42574 3/20 0.47
SENP7 Q9BQF6 3/20 0.47
SENP6 Q9GZR1 3/20 0.47
POLB P06746 2/20 0.47
SENP8 Q96LD8 2/20 0.47
FBP1 P09467 2/20 0.47
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8034874 0.87 MAPT (0.56) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL12829205 0.82 IL6 (0.55) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL18344093 0.82 IL6 (0.62) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL7899328 0.81 RAB9A (0.64) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL23010587 0.80 RAB9A (0.52) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL11451768 0.77 ELANE (0.61) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL5538663 0.75 KDM4E (0.62) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL13436713 0.74 RAB9A (0.66) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL20725934 0.74 RAB9A (0.56) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL128647 0.74 AGPAT2 (0.56) RAB9ANPC1MAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8637542-B2 Kinase inhibitors and methods of use INTELLIKINE, INC. (US) 2014-01-28 US disclosed
EP-1730148-A4 AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS ABBOTT LAB (US) 2009-08-19 EP disclosed
EP-1730148-A2 AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS Abbott Laboratories (US) 2006-12-13 EP disclosed
US-20060025383-A1 Aminobenzoxazoles as therapeutic agents ABBOTT LABORATORIES 2006-02-02 US disclosed
WO-2005074603-A2 AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS ABBOTT LABORATORIES (US) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025383-A1 Aminobenzoxazoles as therapeutic agents ABL1, MAP3K19, MAP3K20 RAB9A 2517/4885NPC1 4475/4885MAPT 2567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.